Altamira Therapeutics Profit Margin

Altamira Therapeutics (CYTO) currently reports a profit margin of 4482.79% as of June 2023. That compares with -2810.27% in the prior-year period — up 259.5% year over year. That is above the Healthcare sector average of 19.13%. Use the charts on this page to explore Altamira Therapeutics's profit margin history and peer comparisons.

Altamira Therapeutics's profit margin increased from -2810.27% to 4482.79% — a 259.5% year-over-year increase (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Altamira Therapeutics's profit margin of 4482.79% is higher than the Healthcare sector average of 19.13%. That is roughly 23331.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Altamira Therapeutics's current 4482.79% should be judged against Healthcare norms (sector average: 19.13%) and against CYTO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 4482.79%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 19.13%. From there, open related valuation or income-statement pages for Altamira Therapeutics, and consider following CYTO for alerts when major investors trade the stock.